Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases

Journal of Viral Hepatitis

Volumn 15, Issue 3, 2008, Pages 212-218

  Sebastiani, G ^a,b   Vario, A ^b   Guido, M ^b   Alberti, A ^a,b  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chronic hepatitis C; Liver fibrosis; Noninvasive markers; Normal transaminases

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; THROMBOCYTE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TRANSAMINASES;

EID: 38449096793     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00932.x     Document Type: Article

References (32)

1. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999 6 : 35 47.
2. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999 31 (Suppl. 1 17 24.
3. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
4. Sebastiani G, Alberti A. Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006 12 : 3682 3694.
5. Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005 42 : 838 845.
6. Poynard T, Munteanu M, Ngo Y et al. Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 2006 43 : 374 375.
7. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005 42 : 266 274.
8. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000 32 : 477 481.
9. Almasio PL, Niero M, Angioli D et al. Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol 2005 43 : 381 387.
10. Koda M, Matunaga Y, Kawakami M et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007 45 : 297 306.
11. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997 3 (Suppl. 1 S133 S136.
12. Schlichting P, Holund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 1983 18 : 27 32.
13. Hubscher SG. Histological grading and staging in chronic hepatitis: clinical applications and problems. J Hepatol 1998 29 : 1015 1022.
14. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004 99 : 1160 1174.
15. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004 50 : 1344 1355.
16. The French Cooperative Study Group. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
17. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 526.
18. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 : 986 992.
19. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 1075.
20. Giannini E, Risso D, Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003 163 : 218 224.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 : 837 845.
22. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York : John Wiley & Sons, 2002.
23. Puoti C, Guido M, Mangia A et al. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003 35 : 362 369.
24. Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004 127 : 1724 1732.
25. Fabris C, Smirne C, Toniutto P et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006 39 : 339 343.
26. Castera L, Foucher J, Bertet J et al. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 2006 43 : 373 374.
27. Sebastiani G, Vario A, Guido M et al. Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006 44 : 686 693.
28. Thabut D, Simon M, Myers RP et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003 37 : 1220 1221.
29. Naveau S, Poynard T, Benattar C et al. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994 39 : 2426 2432.
30. Poynard T, Halfon P, Castera L et al. Prevalence of each fibrosis stage is a major factor of variability when assessing the area under the ROC curves in the evaluation of liver fibrosis markers. J Hepatol 2007 : 46 (Suppl. 1 S211 [abstract].
31. Colloredo G, Guido M, Sonzogni A et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003 39 : 239 244.
32. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004 127 : 1704 1713.